Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal Allogeneic CAR T-cell Therapy in Autoimmune Hemolytic Anemia
NCT06733610Phase 1Active, not recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2024
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in autoimmune hemolytic anemia (AIHA), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 12 months and 1 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT06733610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06733610.